Genentech announced FDA has accepted the company’s supplemental Biologics License Application for Tecentriq (atezolizumab) in combination with Abraxane (albumin-bound paclitaxel; nab-paclitaxel) and carboplatin for the initial treatment of people with metastatic non-squamous non-small cell lung cancer who do not have EGFR or ALK genomic tumor aberrations.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
